Page 42 - 66_01

J. CORTIJO ANAL. REAL ACAD. FARM.

BIBLIOGRAFÍA

(1) BAOS V, SEOANE F.J. Asma bronquial. MEDIFAM, (1994); 4 (6):
266-275.

(2) TORPHY T.J, UNDEM D.J. Phosphodiesterase inhibitors: New
opportunities for the treatment of asthma. Thorax, (1991); 46: 512-523.

(3) BEAVO J.A.. Cyclic nucleotide phosphodiesterases: functional
implications of multiple isoforms. Physiol. Rev., (1995); 75: 725-748.

(4) TEIXEIRA M.M, GRISTWOOD R.W, COOPER N, et al..
Phosphodiesterase (PDE) 4 inhibitors: anti-inflammatory drugs of the
future?. TiPS, (1997); 18: 164-170.

(5) TORPHY T.J. Phosphodiesterase isozymes. Molecular targets for novel
antiasthma agents. Am J Respir Crit Care Med, (1998); 157: 351-370.

(6) THOMPSON W.J. Cyclic nucleotide phosphodiesterases:

pharmacology, biochemistry and function. Pharmacol Ther, (1991); 51:

13-33.

(7) NICHOLSON C.D, SHAHID M. Inhibitors of cyclic nucleotide
phosphodiesterase isoenzymes— their potential utility in the therapy of
asthma. Review. Pulmonary Pharmacology, (1994); 7: 1-17.

(8) MANGANIELLO V.C, MURATA T, TAIRA M, et al.. Diversity in
cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem
Biophys., (1995); 322: 1-13.

(9) BOLGER G.B. Molecular biology of the cyclic AMP-specific cyclic
nucleotide phosphodiesterases: a diverse family of regulatory enzymes.
Cell Signal., (1994); 6: 851-859.

(10) CONTI M, NEMOZ G, SETTE C, et al.. Recent progress in
understanding the hormonal regulation of phosphodiesterases. Endocr.
Rev., (1995); 16: 370-389.

(11) SCHUDT C, TENOR H, HATZELMANN A. PDE isoenzymes as
targets for anti-asthma drugs. Eur Respir J, (1995); 8: 1179-1183.

(12) THOMAS M.K, FRANCIS S.H, CORBIN J.D. Characterization of a
purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol
Chem,(1990a); 265: 14964 -14970.

(13) THOMAS M.K, FRANCIS S.H, CORBIN J.D. Substrate- and kinase-
directed regulation of phosphorylation of a cGMP-binding
phosphodiesterase by cGMP. Biol Chem, (1990b); 265: 14971-14978.

20